New insider activity at Kura Oncology ( (KURA) ) has taken place on September 29, 2025.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Several key executives at Kura Oncology have recently sold significant portions of their stock. President & CEO Troy Edward Wilson led the transactions by selling 36,615 shares, amounting to $327,338. CMO Mollie Leoni followed with the sale of 12,314 shares worth $110,087. CCO Brian T. Powl sold 8,891 shares for $79,485, while CLO Teresa Brophy Bair sold 8,805 shares for $78,716. COO Kathleen Ford and SVP, Finance & Accounting Thomas James Doyle sold 6,892 and 4,541 shares, valued at $61,614 and $40,596, respectively.
Recent Updates on KURA stock
In the past 24 hours, Kura Oncology has seen significant developments, particularly with its investigational drug ziftomenib. The company, in collaboration with Kyowa Kirin, dosed the first patient in the KOMET-017 clinical trial, which aims to evaluate ziftomenib in acute myeloid leukemia (AML) patients. Additionally, the Journal of Clinical Oncology published positive results from the KOMET-001 trial, showing ziftomenib met its primary endpoint with a promising complete remission rate, which is under FDA priority review. Despite these advancements, Guggenheim initiated coverage with a Neutral rating, citing challenges in market competition for the targeted AML segment. Furthermore, Citizens JMP and BofA lowered their price targets for Kura Oncology, reflecting concerns over competitive pressures and market conditions.
Spark’s Take on KURA Stock
According to Spark, TipRanks’ AI Analyst, KURA is a Neutral.
Kura Oncology faces challenges typical of biotech firms in transition, with positive revenue growth yet struggling profitability. Significant milestones in drug applications and a strong cash position are positive, but technical indicators and valuation metrics present caution. The company’s stock performance reflects these mixed factors.
To see Spark’s full report on KURA stock, click here.
More about Kura Oncology
YTD Price Performance: 4.26%
Average Trading Volume: 1,632,548
Technical Sentiment Signal: Hold
Current Market Cap: $785.5M